Home›Stock Screener›Kilitch Drugs

Kilitch Drugs Share Price Today | Stock Price & Kilitch Drugs Share Screener

KILITCH Pharmaceuticals & Biotechnology
Live Share Price NSE
₹236.95
▲ 6.83 (2.97%)
2026-11-19 00:00:00
Live Share Price BSE
₹234.65
▲ 3.75 (1.62%)
2026-11-19 00:00:00

As of November 19, 2026, the live Kilitch Drugs share price (NSE: KILITCH) is ₹236.95 on NSE and ₹234.65 on BSE, up 2.97% from the previous close, with shares trading between ₹228.82 and ₹240.00 in today's trading session, and a 52-week range of ₹124.45–₹369.00. Track KILITCH market value to gauge the company's total market size. Use the Kilitch Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Kilitch Drugs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹90 and net income of ₹15, with EBITDA of ₹23, an operating margin of 25.0% and a profit margin of 16.7%.

Kilitch Drugs Market Cap ₹752.06 Cr.
KILITCH P/E Ratio (TTM) 31.10
Kilitch Drugs P/B Ratio 2.43
EPS (TTM) ₹8.91
Dividend Yield -
Debt to Equity 0.29
KILITCH 52 Week High ₹369.00
Kilitch Drugs 52 Week Low ₹124.45
Operating Margin 25.00%
Profit Margin 16.67%
KILITCH Revenue (TTM) ₹90.00
EBITDA ₹23.00
Net Income ₹15.00
Total Assets ₹458.00
Total Equity ₹277.00

Kilitch Drugs Share Price Chart

Track the current stock price of Kilitch Drugs with an interactive chart. Analyse KILITCH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Kilitch Drugs stock quote in one place.

The quote of ₹236.95 sits between the 52-week low of ₹124.45 and the 52-week high of ₹369.00, and the latest session moved 2.97% from the previous close.

Kilitch Drugs Company Profile - Fundamental Screener

Screen Kilitch Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KILITCH shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE729D01010.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE729D01010

Kilitch Drugs Balance Sheet Screener

Screen KILITCH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹458, up from ₹313 in 2025.

Latest statistics put total assets at ₹458 and shareholder funds at ₹277, with a leverage ratio of 0.29.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 458 313 240 220 210 203 143 144 128 113
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 67 64 62 64 65 30 32 32 33 33

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 59 28 0 0 0 0 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 277 201 176 151 140 130 121 123 113 101
Share Capital 35 16 16 16 16 16 15 15 14 13
Reserves & Surplus 245 186 160 131 121 112 103 106 96 88

Kilitch Drugs Income Statement Screener - Profit & Revenue Analysis

Screen Kilitch Drugs income statement and profit fundamentals. Analyze KILITCH quarterly results. Kilitch Drugs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹90 and net profit was ₹15, equal to earnings per unit of ₹4.24, at an operating margin of 25%.

In that period expenses were ₹68, interest cost ₹1 and tax ₹5. The next period listed, 2026-Jun, shows revenue of ₹48 and net profit of ₹2.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 90 48 52 63 46 56 55 45 36 53 58 47 37 42 35
Expenses 68 42 44 47 40 44 48 38 32 41 47 39 30 33 30

Operating Costs and Margins

EBITDA 23 6 9 16 6 12 8 8 4 11 11 7 7 9 5
Operating Profit % 25.00% 7.00% 13.00% 24.00% 8.00% 10.00% 11.00% 16.00% 5.00% 13.00% 16.00% 14.00% 17.00% 21.00% 7.00%
Depreciation 1 1 4 1 1 1 1 1 1 1 1 1 1 1 1
Interest 1 1 2 2 2 1 1 1 2 0 1 1 2 2 2

Profit and Earnings

Profit Before Tax 20 4 3 14 4 9 6 5 2 10 8 5 5 7 3
Tax 5 2 2 4 1 1 1 2 2 2 3 2 2 2 1
Net Profit 15 2 1 10 2 8 4 4 0 9 6 3 3 5 2
EPS 4.24 0.83 0.64 6.47 1.88 4.97 2.50 2.24 0.83 5.36 3.71 2.29 2.15 2.93 1.85

Kilitch Drugs Cash Flow Screener - Liquidity Fundamentals

Screen KILITCH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹24, and net cash flow was an inflow of ₹6.

Over the same period, investing activities used ₹100 and financing activities provided ₹82.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 24 18 -2 3 6 46 5 0 1 1
Investing Activities -100 -40 -8 8 -15 -38 -10 -14 -4 -2

Financing and Net Cash

Financing Activities 82 13 9 -1 7 2 1 17 6 0
Net Cash Flow 6 -9 -1 10 -2 10 -5 3 3 0

Kilitch Drugs Shareholding Pattern Screener

See Kilitch Drugs shareholding pattern with promoter, FII, and DII holdings. Check Kilitch Drugs promoter holding and ownership changes for KILITCH on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 63.77%, foreign institutions 0.00%, domestic institutions 0.00% and the public 29.70%, spread across 11,642 shareholders.

The shareholder count was 11,642 in 2026-Mar, compared with 12,627 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 63.77% 63.77% 63.77% 69.23% 69.23% 63.77% 63.77% 69.23%

Institutional Investors

FII Holding 0.00% 0.12% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.50% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 29.70% 29.64% 29.03% 25.57% 25.54% 30.22% 31.04% 25.37%
Other Holding 6.52% 6.47% 6.60% 5.20% 5.23% 6.01% 5.18% 5.39%
Shareholder Count 11,642 12,627 12,319 9,749 10,379 10,929 12,043 9,525

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Kilitch Drugs. Kilitch Drugs dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.50 0.62%
2018-March ₹0.50 0.26%
2017-March ₹0.00 0.00%

Kilitch Drugs Stock Index Membership - Nifty & Sensex

See which indices include Kilitch Drugs stock. Check KILITCH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Kilitch Drugs is not part of any tracked indices.
Only major market indices are tracked in our system.

Kilitch Drugs Market Events Screener - Corporate Actions

Get Kilitch Drugs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Kilitch Drugs stock events that may affect KILITCH share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Extraordinary General Meeting dated November 16, 2026, with a record date of November 16, 2026.

It is followed by Quarterly Result Announcement dated November 6, 2026 and Extraordinary General Meeting dated October 16, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-16 2026-11-16 Extraordinary General Meeting NA 6.43%
2026-11-06 2026-11-06 Quarterly Result Announcement NA 3.55%
2026-10-16 2026-10-16 Extraordinary General Meeting NA 15.95%
2026-08-27 2026-08-27 Annual General Meeting NA -5.30%
2026-08-13 2026-08-13 Quarterly Result Announcement NA -1.21%
2026-05-15 2026-05-15 Quarterly Result Announcement NA 0.35%
2026-03-24 2026-03-24 Bonus 1:1 -0.91%
2026-03-13 2026-03-13 Extraordinary General Meeting NA -11.19%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 10.00%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -2.38%
2025-09-26 2025-09-26 Annual General Meeting NA 2.13%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -0.01%
2025-07-15 2025-07-15 Rights 2:23 15.19%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 4.81%
2025-02-11 2025-02-11 Quarterly Result Announcement NA 2.20%

Kilitch Drugs Competitors Screener - Peer Stocks Comparison

Screen KILITCH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Kilitch Drugs Company Announcements - News & Reports Screener

Screen KILITCH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 17, 2026 and November 17, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-17 Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Corrigendum To The Notice Of Extra Ordinary General Meeting (EGM Notice). -
2026-11-17 Rectification Of Typo Error In The Outcome Of Board Meeting Dated 22Nd October 2026 -
2026-11-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-11 Board Meeting Outcome for Outcome Of Board Meeting -
2026-11-11 Unaudited Financial Results -
2026-11-02 Board Meeting Intimation for Consider And Approval Of Unaudited Standalone And Consolidated Financials Results For The Quarter And Half Year Ended 30Th September 2026 -
2026-10-26 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-23 Notice Of EGM -
2026-10-23 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-22 Board Meeting Outcome for Outcome Of Board Meeting -
2026-10-21 Announcement under Regulation 30 (LODR)-Resignation of Director -
2026-10-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-28 Closure of Trading Window -
2026-08-27 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-27 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-18 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-08-18 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-13 Board Meeting Outcome for Financial Results For The Quarter Ended 30Th June 2026 -
2026-08-13 Financial Results For The Quarter Ended 30Th June 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹236.95, within a 52-week range of ₹124.45 to ₹369.00. The P/E ratio is 31.10 and the P/B ratio is 2.43, with earnings per unit of ₹8.91. Market capitalisation stands at ₹752.06 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.